PreTerm Birth Clinical Trial
Official title:
New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women
The QUIPP tool integrates information of obstetrical history, quantitative fetal fibronectin
(qfFN) and cervical length to predict the risk of sPTB in asymptomatic high-risk women.
The aim of this study is to evaluate the QUIPP tool in our setting in order to optimize the
management of women at high risk for sPTB and to validate in a randomized clinical trial,
whether the use of QUIPP improves efficiently the management of our asymptomatic high-risk
women when it is compared with the current clinical management.
Design: Randomized controlled trial. Inclusion criteria: Asymptomatic singleton pregnancies
18,0-22,6 weeks at high-risk for sPTB. Sample size: According to a non-inferiority analysis,
129 pregnant women will be needed for each arm.
Methodology: Patient selection and who consent to participate in the study will be
randomized into two arms: a) Intervention group: QUIPP tool will be used to select and
manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and
low-risk patients will be discharged from PBPC and managed in a low-risk unit. b) Control
group: Women will be managed according to current clinical practice.
Main Outcome: sPTB <34,0 and <37,0 weeks of gestation. Secondary Outcomes: Pregnancy
outcomes and a neonatal composite morbidity. Expected Results: Perinatal outcomes are
similar in the intervention and control group although the intervention group using the
QUIPP tool required less medical resources.
Preterm birth (PTB) is a leading cause of perinatal morbidity and mortality. Women at
high-risk of preterm birth are those with a previous spontaneous preterm birth (sPTB) or
preterm premature rupture of membranes before 35 weeks of gestation, uterine malformation,
surgery on uterine cervix or a short cervical length; these women have a global risk of PTB
about 30% but still 75%-85% of these women will deliver at term without any intervention.
The availability of a specialized Preterm Birth Prevention Clinic (PBPC) is relevant for the
management of these high-risk pregnant women and it results in a reduction in the risk of
recurrent sPTB, pregnancy prolongation and a reduction in the rate of major neonatal
morbidity. However, it implies higher outpatient care costs as well as trained personnel and
intensive follow-up management even for those women not destined to deliver preterm QUIPP is
a free smartphone application that integrates the obstetrical history of high-risk women,
the cervical length and the value of quantitative fetal fibronectin to predict the risk of
preterm birth. QUIPP will determinate the risk of preterm birth in these high-risk women.
Patients will be randomized in two groups: Intervention group (QUIPP tool arm): QUIPP tool
is applied and patients with a high-risk result will be follow-up in a high-risk unit (PBPC)
and patients with a low-risk value will be managed in a low-risk unit. Control group (no
QUIPP tool arm): current management in a PBPC will be applied.
The use of QUIPP will allow determining which asymptomatic pregnancies with risk factors for
sPTB will deliver preterm. Furthermore, we expect to provide the non-specialized clinician
with an objective, useful, accurate and efficient tool to manage these women with same
pregnancy and neonatal outcomes and using less resource.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Completed |
NCT05502510 -
Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
|
||
Not yet recruiting |
NCT03418012 -
Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB
|
N/A | |
Not yet recruiting |
NCT03418311 -
Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome
|
N/A | |
Completed |
NCT02993744 -
Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone
|
N/A | |
Active, not recruiting |
NCT02673216 -
Infection and Adverse Pregnancy Outcome
|
||
Completed |
NCT01683565 -
Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood
|
Phase 4 | |
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Completed |
NCT01412931 -
Protein and Ultrasound Indicators of Preterm Birth
|
N/A | |
Completed |
NCT02606058 -
The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?
|
N/A | |
Terminated |
NCT03715530 -
Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women
|
N/A | |
Completed |
NCT00422526 -
Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial
|
Phase 3 | |
Enrolling by invitation |
NCT04251260 -
Effectiveness of Positioning in Preterm Neonates
|
N/A | |
Completed |
NCT03668860 -
India Dexamethasone and Betamethasone
|
Phase 1 | |
Recruiting |
NCT03638037 -
Correlation Between Maternal Vitamin D Level And Preterm Birth
|
||
Completed |
NCT02225353 -
Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
|
Phase 2 | |
Recruiting |
NCT03992534 -
The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth
|
Phase 1 | |
Completed |
NCT03144141 -
Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery
|
N/A | |
Completed |
NCT05210985 -
Examination of the Relationship Between Home Affordances With Development
|
||
Completed |
NCT04021654 -
What is the Future of Vulnerable New-borns
|